A238200 Stock Overview
BIFIDO Co., Ltd produces probiotics based products in South Korea, China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BIFIDO Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,270.00 |
| 52 Week High | ₩9,390.00 |
| 52 Week Low | ₩4,815.00 |
| Beta | 1.01 |
| 1 Month Change | -8.98% |
| 3 Month Change | 1.35% |
| 1 Year Change | -32.09% |
| 3 Year Change | -49.33% |
| 5 Year Change | -69.58% |
| Change since IPO | -71.12% |
Recent News & Updates
Shareholder Returns
| A238200 | KR Personal Products | KR Market | |
|---|---|---|---|
| 7D | 3.1% | -0.7% | -0.4% |
| 1Y | -32.1% | -2.9% | 4.5% |
Return vs Industry: A238200 underperformed the KR Personal Products industry which returned -2.9% over the past year.
Return vs Market: A238200 underperformed the KR Market which returned 4.5% over the past year.
Price Volatility
| A238200 volatility | |
|---|---|
| A238200 Average Weekly Movement | 6.8% |
| Personal Products Industry Average Movement | 5.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A238200's share price has been volatile over the past 3 months.
Volatility Over Time: A238200's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 99 | n/a | www.bifido.com |
BIFIDO Co., Ltd produces probiotics based products in South Korea, China and internationally. It offers bifidobacterium strain products, such as BGN4 for immune modulating; BORI used to treat rotavirus infection in infants; and AD011 for general intestinal health problems. The company was founded in 1999 and is headquartered in Hongcheon-eup, South Korea.
BIFIDO Co., Ltd. Fundamentals Summary
| A238200 fundamental statistics | |
|---|---|
| Market cap | ₩43.11b |
| Earnings (TTM) | ₩1.08b |
| Revenue (TTM) | ₩18.63b |
39.8x
P/E Ratio2.3x
P/S RatioIs A238200 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A238200 income statement (TTM) | |
|---|---|
| Revenue | ₩18.63b |
| Cost of Revenue | ₩11.21b |
| Gross Profit | ₩7.42b |
| Other Expenses | ₩6.34b |
| Earnings | ₩1.08b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 132.29 |
| Gross Margin | 39.83% |
| Net Profit Margin | 5.81% |
| Debt/Equity Ratio | 22.0% |
How did A238200 perform over the long term?
See historical performance and comparison